This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maini RN et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563
St Clair EW et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 50: 3432–3443
Lipsky, PE et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602
Klareskog L et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681
Smolen JS et al. (2005) Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT trial. Arthritis Rheum 52: 1020–1030
Smolen JS and Aletaha D (2004) Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 63: 221–225
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JS Smolen is an advisory board member for several companies, including Abbott, Centocor, Schering-Plough and Wyeth. He was also principal investigator on the ASPIRE trial.
Rights and permissions
About this article
Cite this article
Smolen, J., Aletaha, D. Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?. Nat Rev Rheumatol 2, 242–243 (2006). https://doi.org/10.1038/ncprheum0171
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0171